American Medical Systems Holdings, Inc. (AMMD) reported strong fiscal third quarter results. For the quarter, earnings per share was 27 cents, beating the Zacks Consensus Estimate of 20 cents and the year-ago earnings of 18 cents. Earnings per share for the reported quarter were also ahead of the company’s previous guidance of 17 to 21 cents.   Sales   Total sales for the quarter increased 4.9% year over year to $123.2 million. Excluding an unfavorable foreign currency translation (FX), net sales increased 6.7% year over year. On a geographic basis, U.S. sales accounted for roughly 75% of total sales and increased 9.2% year over year. International sales declined 6.1% year over year.   In terms of business segments: Men’s health revenues increased 6.6% year over year to $54.7 million. Growth was primarily due to higher sales of the erectile restoration system.   Women’s health revenues increased 4% year over

...

Oxygen Biotherapeutics now has a clinical development pipeline which includes seven indications for Oxycyte(TM) emulsion. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier. The new Oxycyte pipeline includes: Traumatic Brain Injury, Carbon Monoxide Poisoning, Surgical Iatrogenic Air Embolism, Spinal Cord Injury, Organ Preservation, Decompression Sickness, and Sickle Cell Crisis.

The company has also reported that its topical pipeline includes six additional indications in development for the Oxycyte Gel. The first use of the Dermacyte Gel is for a cosmetic line that is now available for pre-orders via the BuyDermacyte.com website, with product shipment expected in about four weeks. Other uses include treatment for Wounds, Burns, Acne, Rosacea, Cell Treatment after Radiation Therapy, and Erectile Dysfunction. Oxygen Biotherapeudics is also working on two additional uses for Oxycyte Compounds, including a ventilation device called VitaVent and a Deep Immersion Fluorocarbon Treatment for severe burns.

Oxygen Biotherapeutics CEO Chris Stern commented on the

...

Medtronic, Inc. (MDT) recently started a feasibility study of an interventional treatment for erectile dysfunction (ED) using a specially designed drug-eluting stent system. The study is known as ZEN (Zotarolimus-Eluting Peripheral Stent System for the Treatment of Erectile Dysfunction in Males with Sub-Optimal Response to PDE5 Inhibitors) and is being conducted under an investigational device exemption (IDE) issued by the U.S. Food and Drug Administration (FDA).   The study is expected to enroll 50 patients at up to ten medical centers in the United States over 2010. It has been seen that there is a link between erectile dysfunction and coronary artery disease. ED is primarily caused by vascular disease due to the deterioration of the endothelium. Medtronic’s drug-eluting stent preserves endothelial function of the native vessels. The study evaluates the safety and enhanced erectile function of pelvic artery stenting. Results are expected in 2011.      If successfully

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Tuesday October 13, 2009

DrStockPick.com Stock Report!

**************************************************************

Cavitation Technologies, Inc. (OTC Bulletin Board: CVAT) has announced that it has filed PCT patent applications for new International Patent protections for its Nano Cavitation Technologies

Medtronic, Inc. (NYSE: MDT), announced today the initiation of a feasibility study of an interventional treatment for erectile dysfunction (ED) that uses a specially-designed drug-eluting stent system. The study, called ZEN (Zotarolimus-Eluting Peripheral Stent System for the Treatment of Erectile Dysfunction in Males with Sub-Optimal Response to PDE5 Inhibitors), is being

...

American Medical Systems Holdings, Inc. (AMMD) recently won a new contract to supply three of its female stress urinary incontinence (SUI) treatment devices, Monarc Subfascial Hammock, MiniArc Single-Incision Sling, and SPARC Sling System, in the U.K. The contract was awarded by the public healthcare provider of the U.K. , the National Healthcare Services (NHS), as part of its multiple-awardees contract. Financial details of the contract are yet to be disclosed.  The devices will be available to women treated in any NHS hospital in the region and supported by the Normanton centre, U.K. The Monarc device is one of the leading transobturator slings that bring relief to women suffering from SUI. It has been estimated that more than 600,000 women have been implanted with the Monarc, MiniArc and SPARC systems globally.  We think that the new contract is a shot in the arm for American Medical Systems ...

American Medical Systems Holdings, Inc. (AMMD) amended its offer to exchange up to $250 million and a minimum of $100 million of its outstanding 3.25% Convertible Senior Subordinated Notes due 2036 for newly issued 3.75% Convertible Senior Subordinated Notes due 2041.

The amendment pertains to the coupon rate that was increased 25 basis points to 4.00%. The exchange offer will close on Sep 16, 2009 at midnight. All other terms and conditions for the exchange offer remain unchanged.

The exchange offer calls for exchange of each $1,000 principal amount of its new 3.75%, now 4.00%, Convertible Senior Subordinate Notes due 2041, for each $1,000 principal amount of its 2036 Notes. The 2041 Notes will be converted into cash or shares of the company's common stock at the same conversion rate and price as the 2036 Notes.

The terms and conditions of the exchange offer suggest that holders of 2041 Notes will

...

One Down, One To Go For United TherapeuticsOn May 25, 2009, the U.S. FDA approved United Therapeutics (UTHR) Adcirca (tadalafil, sold by Eli Lilly [LLY] as Cialis for erectile dysfunction) for the treatment of pulmonary arterial hypertension (PAH), with a recommended dose of 40 mg. Adcirca is indicated to improve exercise ability in WHO Group I PAH patients, which encompasses patients with multiple forms of PAH including etiologies such as idiopathic and familial PAH as well as PAH associated with scleroderma and congenital heart disease.Our financial model assumes that United Therapeutics can start recording sales of tadalafil for PAH in August 2009. We assume only modest contribution in 2009, so a stronger-than-expected launch would lead to upside to our financial model.On April 26, 2009, United Therapeutics was notified by the U.S. FDA that its pending review of the inhaled version of ...

American Medical Systems (...

American Medical Systems (...

United Therapeutics Corp. (UTHR) posted financial results for the first quarter 2009 on May 1, 2009. Total revenues for the quarter were $79.7 million, up 29% from the first quarter in 2008. Revenues consisted of $76.9 million in sales of IV/SC Remodulin and $2.9 million in service, distributor and licensing fees.Net income on a GAAP basis totaled $13.2 million, up 16% from last year. This equated to EPS of $0.49. Net income adjusted for non-cash expenses, including stock-based compensation, amortization or debt expense, depreciation and amortization, and non-cash taxes, totaled $37.0 million, an increase of 43% from the adjusted first quarter in 2008, and equated to $1.36 in adjusted EPS. This was roughly 28% growth over the first quarter in 2008. United Therapeutics exited the first quarter 2009 with $319.4 million in cash and equivalents.United Therapeutics currently has two pending applications with the U.S. ...